Condition: Low Risk Myelodysplastic Syndromes · Sponsor: Rigel Pharmaceuticals
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
This description comes directly from the study's public registry record.
Strait Hicklin · (650) 624-1100 · shicklin@rigel.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| Stanford Cancer Institute | Palo Alto, California, United States | Not Yet Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Mount Sinai Medical Center | Miami Beach, Florida, United States | Withdrawn |
| WashU Medicine | St Louis, Missouri, United States | Not Yet Recruiting |
| Oncology Clinical Research Referral Office | Hackensack, New Jersey, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Withdrawn |
| Ichan School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
| Duke Cancer Institute | Durham, North Carolina, United States | Not Yet Recruiting |
| Cleveland Clinic | Cleveland, Ohio, United States | Recruiting |
| The Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05308264